Sponsored

Radiopharm Theranostics (ASX: RAD) to raise AU$1.7M through entitlement offer shortfall - Kalkine Media

January 24, 2024 12:44 PM AEDT | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • RAD has received commitments for a placement of over 24 million shares under an entitlement offer shortfall.
  • The amount raised through theentitlement offer shortfall will be approximately AU$1.7 million.
  • The funds raised will support RAD’s clinical programs.

Radiopharm Theranostics Limited (ASX: RAD) has received commitments for nearly AU$1.7 million for a shortfall under an entitlement offer. The entitlement offer shortfall will entail the issue of 24,025,716 shares at an issue price AU$0.07 per share.

The funds raised will support the clinical programs of the company.

On 30 January 2024, the shares issued under shortfall will be settled and on 31 January 2024, shares are planned to be allotted.

About the entitlement offer

In October 2023, the company had announced a non-renounceable entitlement offer for one new RAD share for every 2.35 RAD shares held at AU$0.07 issue price.

Through the offer, the company raised nearly AU$2.1 million by issuing 30,197,244 shares. More.

RAD shares traded at AU$0.075 apiece at the time of writing on 24 January 2024.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



Top ASX Listed Companies


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.